Kevin Zorn, MD, FRCSC, FACS, presented “Office BPH: 2024 Updates and Where Are We Going?” during the 2024 Frontiers in Oncologic Prostate Care and Ablative Local Therapy symposium on October 18, 2024, in San Diego, California.
>
How to cite: Zorn, Kevin. “Office BPH: 2024 Updates and Where Are We Going?.” October, 2024. Accessed Feb 2026. https://grandroundsinurology.com/office-bph-2024-updates-and-where-are-we-going/
Office BPH: 2024 Updates and Where Are We Going? – Summary
Kevin Zorn, MD, FRCSC, FACS, explores the evolving approaches to treating benign prostatic hyperplasia (BPH), emphasizing the need for early intervention and office-based procedures.
In this 15-minute presentation, Dr. Zorn addresses the growing global population of men requiring treatment, highlighting the increasing demand for efficient, minimally invasive solutions. He reviews the progression of technologies, including UroLift, Rezūm, and newer systems like OptilumeⓇ, which offer quick recovery, durability, and adaptability to patient needs.
Dr. Zorn underscores the importance of understanding prostatic architecture to tailor treatments. He discusses the evolution and reproducibility of stent-based technologies, comparing them to individualized techniques like UroLift. He highlights the critical role of imaging and anatomical assessment in refining procedural precision and selecting the best therapeutic approach for each patient.
Dr. Zorn advocates for advancements in local anesthesia techniques, enabling more procedures in office settings with improved patient comfort. By integrating these technological and procedural advancements, he envisions a future of personalized, effective, and accessible BPH care that maximizes outcomes while addressing the rising clinical demand.
Frontiers in Oncologic Prostate Care and Ablative Local Therapy (FOCAL) is an outstanding program on prostate imaging, transperineal interventions, and ablative treatments for prostate cancer and benign prostatic hyperplasia. Bringing together community-based, academic, and industry partners, FOCAL offers lectures by world-renowned faculty and hands-on training workshops on in-office transperineal interventions, fusion-guided prostate ablation and state-of-the-art BPH management with novel technologies.
ABOUT THE AUTHOR
Kevin C. Zorn, MD, FACS, FRCSC, is the Founder and Director at BPH Canada Prostate Institute in Montréal, Canada. Dr. Zorn also serves as Director of Urology and BPH Prostate MIS Surgery at the Centre de chirurgie Mont-Royal. His main focus of clinical and scientific interest is the surgical treatment of renal and prostate cancer. He is also an expert in performing surgery with the daVinciⓇSurgical Robotic System to manage localized prostate cancer and small renal masses.
Dr. Zorn attended McGill University in Montréal for his pre-med program, his medical degree, and his residency in Urological Surgery. He became a Fellow of the Royal College of Physicians and Surgeons of Canada (FRCSC) in 2005. Dr. Zorn also completed a fellowship in oncology and endourology at the University of Chicago. In 2007, he became certified by the American Board of Urology in urology and a Fellow of the American College of Surgeons.
Dr. Zorn was the first in Canada to use many new BPH technologies, including Greenlight XPS, Rezum, iTind, Optilume, Aquablation, and Zenflow. He has also been the first in Canada to introduce cutting-edge technologies, including the Clarius and ButterflyIQ point-of-care ultrasound (POCUS), as well as disposable AMBU4 cystoscopes for faster patient care and greater safety. Dr. Zorn is among the first physicians globally to be named as a Center of Excellence for Rezum and Greenlight vaporization and VIT (vapor incision technique). He is an international speaker and surgical trainer for these techniques.
Dr. Zorn is the senior author of theMale Lower Urinary Tract Symptoms (LUTS)/BPH Guidelinesfor the 2018 and 2022 Canadian Urological Association (CUA) and consulted on the American Urological Association BPH guidelines. He has also helped create national online programs in robotic prostate cancer care and rehabilitation, as well as the CUA BPH patient decision-aid tool. Dr. Zorn has authored 400 peer-reviewed publications and 12 book chapters on BPH and minimally invasive surgical care.
